	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	R 2025 Mar 31	2026 Mar 31	TTM Jun 30
	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	R 2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M IR
Total Revenue	377	832	1,008	1,320	1,340	1,051	2,609	2,269	2,142
Cost of Operating Revenue	154	344	447	589	616	487	1,091	972	827
Gross Profit	223	488	561	731	724	564	1,518	1,296	1,315
Gross Margin	59.1	58.7	55.7	55.4	54.0	53.7	58.2	57.1	61.4
Total Operating Expenses	214	470	599	780	822	697	1,944	2,022	2,017
Operating Profit	163	361	409	541	519	355	665	246	124
Operating Margin	43.2	43.4	40.6	40.9	38.7	33.7	25.5	10.9	5.8
Financing Income/(Expense) - Net	-5	-12	1	10	38	48	-21	-29	-34
Profit before Taxes	158	405	468	668	560	406	643	207	101
Income Taxes	49	88	105	214	148	105	158	57	43
Profit after Tax	109	317	362	454	411	300	487	179	106
PAT Margin	29.0	38.1	35.9	34.4	30.7	28.6	18.7	7.9	5.0
EPS - Basic - ex Extraordinary Items	4.29	12.45	14.23	17.83	16.16	11.80	12.79	4.69	2.78
EPS - Diluted - ex Extraordinary Items	4.29	12.45	14.23	17.83	16.16	11.80	12.70	4.68	2.77
EBIT	163	361	409	541	519	355	665	246	124
EBITDA	174	385	440	580	567	409	831	434	316
EBITDA Margin	46.2	46.3	43.7	43.9	42.3	38.9	31.9	19.1	14.8

Balance Sheet

Abridged

Understanding Balance Sheet

Cohance Lifesciences Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	R 2025 Mar 31	2026 Mar 31
	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	R 2025 Mar 31	2026 Mar 31
Source:	AR	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	390	392	565	1,128	1,011	1,263	1,758	1,796
Long-Term Investments	0	0	0	-	-	9	0	2
Property Plant & Equipment - Net	379	456	535	562	766	787	2,096	2,163
Total Non-Current Assets	393	781	910	702	955	991	3,723	3,933
Total Assets	783	1,173	1,474	1,830	1,966	2,254	5,481	5,730
Total Current Liabilities	158	200	220	210	159	107	705	646
Long Term Debt	-	92	36	29	5	21	321	256
Total Non-Current Liabilities	35	128	74	92	72	97	983	1,050
Total Liabilities	193	328	294	302	231	203	1,688	1,696
Total Shareholders' Equity	590	845	1,181	1,527	1,735	2,051	3,649	3,911
Minority Interest	-	-	-	-	-	-	144	123
Total Equity	590	845	1,181	1,527	1,735	2,051	3,793	4,034
Total Liabilities & Equity	783	1,173	1,474	1,830	1,966	2,254	5,481	5,730

Cash Flow

Abridged

Understanding Cash Flow Statement

Cohance Lifesciences Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2019 Mar 31	2020 Mar 31	C 2021 Mar 31	2022 Mar 31	C 2023 Mar 31	2024 Mar 31	R 2025 Mar 31	2026 Mar 31
	2019 Mar 31	2020 Mar 31	C 2021 Mar 31	2022 Mar 31	C 2023 Mar 31	2024 Mar 31	R 2025 Mar 31	2026 Mar 31
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	136	351	386	518	446	306	639	316
Working Capital - Increase/(Decrease)	-88	45	-12	-194	6	47	-1	21
Net CF from Operating Activities	48	396	374	324	451	353	638	337
Capital Expenditures - Net	57	99	111	75	286	52	317	199
Net CF from Investing Activities	-66	-422	-311	-136	-201	-364	-391	-258
Dividends Paid - Cash - Total	23	77	25	102	204	-	-	-
Stock - Issuance/(Retirement) - Net	-	-	-	-	-	-	9	32
Debt - LT & ST - Issuance/(Retirement) - Total	52	103	-42	-48	-27	-6	-300	-113
Net Cash Flow from Financing Activities	29	27	-67	-150	-230	-6	-291	-131
Free Cash Flow to Equity	43	400	222	200	139	295	22	24
Free Operating CF net dividend	-32	220	238	147	-38	301	321	117
Free Operating CF	-9	297	263	249	166	301	321	117

Business Segment Analysis

FY End:

Mar 26

Cohance Lifesciences Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

pharmaceuticals (100.0%)₹ 219.88 Cr

Revenue / Sales

pharmaceuticals (100.0%)₹ 2,268.55 Cr

Assets

pharmaceuticals (100.0%)₹ 5,729.64 Cr

Operating Income

pharmaceuticals (100.0%)₹ 246.35 Cr

Regional Segment Analysis

FY End:

Mar 26

Cohance Lifesciences Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

Europe (32.2%)₹ 721.94 CrUSA (30.0%)₹ 672.50 CrOthers (23.6%)₹ 529.10 CrIndia (14.2%)₹ 317.11 Cr

Historical Segment Analysis

Track how Cohance Lifesciences Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
pharmaceuticals	57	99	111	75	286	52	156	220

Frequently Asked Questions

What is the revenue of Cohance Lifesciences Ltd.?

The latest trailing twelve month revenue of Cohance Lifesciences Ltd. is ₹ 2,141.50 Cr, reflecting a 1-year growth of 41.24% and a 3-year CAGR of 16.65%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Cohance Lifesciences Ltd.?

The latest trailing twelve month net profit (PAT) of Cohance Lifesciences Ltd. is ₹ 106.23 Cr, with a 3-year earnings CAGR of -45.08%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Cohance Lifesciences Ltd.?

The trailing twelve month EBITDA of Cohance Lifesciences Ltd. is approximately ₹ 124.41 Cr (based on an operating margin of 5.81%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Cohance Lifesciences Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Cohance Lifesciences Ltd. is 2.76. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Cohance Lifesciences Ltd.?

The debt-to-equity ratio of Cohance Lifesciences Ltd. stands at 0.10. The interest coverage ratio is 3.68x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Cohance Lifesciences Ltd.?

The estimated book value per share of Cohance Lifesciences Ltd. is 102.23 (derived from a P/B ratio of 4.40 and market price of ₹ 449.85), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Cohance Lifesciences Ltd.?

The trailing twelve month operating cash flow of Cohance Lifesciences Ltd. is ₹ 337.17 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Cohance Lifesciences Ltd. report consolidated or standalone financials?

Cohance Lifesciences Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.